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Abstract
Background: Multiple myeloma (MM) remains incurable despite recent therapeutic advances. RAS mutations are
frequently associated with relapsed/refractory disease. Efforts to target the mitogen-activated protein kinase (MAPK)
pathway with the MEK inhibitor, trametinib (Tra) have been limited by toxicities and the development of resistance.
Dexamethasone (Dex) is a corticosteroid commonly used in clinical practice, to enhance efficacy of anti-myeloma
therapy. Therefore, we hypothesised that the combination of Tra and Dex would yield synergistic activity in RAS-
mutant MM.
Methods: The response of human MM cell lines to drug treatment was analysed using cell proliferation assays,
Western blotting, Annexin V and propidium iodide staining by flow cytometry and reverse phase protein
arrays. The efficacy of trametinib and dexamethasone treatment in the MM.1S xenograft model was assessed
by measuring tumor volume over time.
Results: The Tra/Dex combination demonstrated synergistic cytotoxicity in KRASG12A mutant lines MM.1S and
RPMI-8226. The induction of apoptosis was associated with decreased MCL-1 expression and increased BIM
expression. Reverse phase proteomic arrays revealed suppression of FAK, PYK2, FLT3, NDRG1 and 4EBP1
phosphorylation with the Tra/Dex combination. Notably, NDRG1 expression was associated with the
synergistic response to Tra/Dex. MM cells were sensitive to PDK1 inhibition and IGF1-induced signalling
partially protected from Tra/Dex treatment, highlighting the importance of this pathway. In the MM.1S
tumor xenograft model, only the combination of Tra/Dex resulted in a significant inhibition of tumor
growth.
Conclusions: Overall Tra/Dex demonstrates antiproliferative activity in RAS-mutant MM cell lines associated
with suppression of pro-survival PDK1 signalling and engagement of apoptotic pathways. Our data support
further investigation of this combination in RAS-mutant MM.
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Key points
 The combination of the MEK inhibitor trametinib
and dexamethasone exhibits antiproliferative activity
in models of RAS-mutant multiple myeloma.
 Suppression of PDK1 signalling is identified as a
potential biomarker of response.
Background
In spite of significant progress in treatment development
over the last two decades, the outlook for multiple mye-
loma (MM) patients still remains poor, with only 33% of
patients surviving up to 10 years from diagnosis [1]. The
main reason underlying this is due to the clonal evolu-
tion of this disease, where exposure to anti-MM therap-
ies results in the selective pressure of subclones that
gain a survival advantage through the acquisition of gen-
etic mutations, translating clinically with disease relapse
and progression [2]. Therefore, there has been increasing
focus on identifying those mutations that ‘drive’ disease
progression, to gain a better understanding of the biol-
ogy of the disease and develop more targeted therapies.
The RAS oncogene in particular has gained significant
interest, as this is one of the most frequently mutated
genes in human cancers [3]. In relation to multiple mye-
loma, RAS mutations have been associated with ad-
vanced disease and patients who had become refractory
to immunomodulatory drug (IMiD)- and proteasome in-
hibitor (PI)-based therapies [4, 5]. Based on these find-
ings, there has been an increasing drive to develop
targeted therapies against the RAS-MAPK signalling
pathway in RAS-mutant multiple myeloma, with the
MEK inhibitors (MEKis) showing promise [6].
However, treatment of RAS-mutant tumors with single
agent MEKi has not resulted in significant responses in
the clinical setting [7]. To overcome this, there has been
an increasing focus on combining RAS-MAPK pathway
inhibitors with currently available treatments, particu-
larly the IMiDs, with the combination of pomalidomide
and trametinib being recently explored in RAS-mutant
patients [8, 9]. However, a significant proportion of pa-
tients treated with single agent trametinib from this
study (22 of 58 (35%)) discontinued due to toxicities [8].
Notably none of the myeloma patients from this study
received corticosteroids to counteract the side effects of
trametinib, which is currently recommended for the
management of toxicities associated with BRAF and
MEK inhibitors in melanoma patients [8, 10].
Interestingly, previous work in acute lymphoblastic
leukaemia (ALL) cell lines has shown that resistance to
dexamethasone was potentially driven by RAS-MAPK
signalling, and could be overcome when steroids were
combined with a MEKi [11–13]. Therefore, trametinib
with dexamethasone could be a potentially effective
combination in RAS-mutant MM patients, which could
be more tolerable in this challenging patient cohort,
translating into improved outcomes. The fact that, to
date, we still do not have a clear understanding of the
mechanism by which the glucocorticoid receptor (GR)
mediates MM cell death, makes this an interesting com-
bination to explore further.
Methods
Cell culture
The human myeloma cell lines LP1 NRAS/KRASwildtype,
JJN3 NRASQ61K, L363 NRASQ61H and RPMI-8226
KRASG12A were obtained from Deutsche Sammlung von
Mikroorganismen und Zellkulturen (Germany). The
myeloma cell lines MM.1R and MM.1S KRASG12A, were
kind gifts from Dr. Fabio Mirabella and Dr. Karen
Menezes (Myeloma Research Group, Institute of Cancer
Research, UK). Myeloma cell lines were maintained at
37 °C and 5% CO2 in Roswell Park Memorial Institute
(RPMI) 1640 media supplemented with 10–15% FBS
Good (Pan-Biotech, UK) for a maximum of 3 months
and regularly tested for mycoplasma using the MycoA-
lert PLUS detection kit (Lonza, USA).
Cell proliferation assays
Cell lines were seeded at a density to permit logarithmic
proliferation in triplicate wells in 96 well plates (Corning,
UK). Cell proliferation was measured using either trypan
blue staining (Sigma Aldrich, UK) or CellTiter-Blue (Pro-
mega, USA). For repeated measurements of cell number
over several weeks, cells were maintained between 0.2-2 ×
106 cells/ml where possible, centrifuged and resuspended
in fresh medium containing inhibitors. Trametinib
(GSK1120212) and dexamethasone were purchased from
Selleck Chem and stored in DMSO at − 20 °C. For the cell
proliferation assays, the concentration of drug that caused
50% inhibition of cell proliferation (GI50) relative to the
DMSO control was determined by non-linear regression
using Prism (GraphPad, USA). For experiments with re-
combinant human cytokines/growth factors, cells were in-
cubated with IL-6 or Insulin Growth Factor-1 (Biotechne,
UK) at a concentration of 3 ng/ml or 100 ng/ml respect-
ively in RPMI media supplemented with 0.5% Bovine
Serum Albumin (BSA) for 24 h prior to the addition of
drugs [14, 15].
Flow Cytometry
Apoptosis was quantified using Annexin V-FITC
(eBioscience, United Kingdom) and PI (Sigma Aldrich,
United Kingdom) staining. For cell cycle distribution
analysis, cells were stained with 10 μg/ml PI and ana-
lysed by flow cytometry (LSR II, BD Biosciences, USA)
and BD FACSDiva software (BD Biosciences, USA).
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Immunoblotting
Cells were seeded at a density of 0.5-1 × 106 cells per ml
in 6-well plates (Falcon) at 37 °C/5% CO2. The next day,
drugs were added to each well at a 1:1000 dilution to
achieve the final indicated concentration. After the spe-
cified time period, cells were harvested, washed once in
cold PBS and lysed in 300 μl RIPA buffer (150 mM NaCl,
1% NP40, 0.5% Sodium Deoxycholate, 0.1% SDS, 50 mM
Tris pH 8.0 and Pierce Protease & Phosphatase inhibi-
tors), then sonicated to shear DNA. Protein concentra-
tion was quantified using the Pierce BCA protein assay
kit (ThermoFisher Scientific). Lysates were analyzed by
SDS-PAGE using NuPAGE Bis-Tris 4–12% gradient gels
and then transferred to nitrocellulose membranes using
the iBlot 2 blotting system (ThermoFisher Scientific).
Membranes were blocked with Odyssey TBS blocking
buffer (LI-COR Biosciences, UK) followed by incubation
with primary antibodies at 4 °C overnight. Antibodies
used included the following: AKT (2920), p-AKT
Thr308 (9275), 4EBP1 (9452), p-4EBP1 Thr37/Thr46
(2855), ERK1/2 (9107), p-ERK1/2 Thr202/Tyr204
(9101), FAK (3285), p-FAK Tyr397 (3283), FKBP5
(8245), FLT3 (3462), p-FLT3 Tyr591 (3461), NDRG1
(5196), p-NDRG1 Thr346 (5482), PARP (9452), PDK1
(3062), p-PDK1 Ser241 (3061), PYK2 (3292), p-PYK2
Tyr402 (3291), S6 (2317) and p-S6 Ser240/Ser244 (5364)
were all purchased from Cell Signaling Technologies.
BIM (sc-374,358) and MCL-1 (sc-12,756) were pur-
chased from Santa Cruz, while Vinculin (V9264) was
purchased from Sigma Aldrich and used as loading con-
trol. Proteins were detected as described previously [16].
Blot images were cropped for clarity of presentation, ori-
ginal blots are provided in the supplementary data.
Reverse Phase Protein Array
Reverse Phase Protein Array (RPPA) analysis was carried
out at The Edinburgh Cancer Discovery Unit using
established protocols for nitrocellulose-based arrays [17].
A custom panel of 60 antibodies targeting key signal
transduction pathways was assembled (Table S1). Briefly,
cell lines were seeded at density of 1 × 106 cells/ml, the
following day compounds were added to each well at di-
lution 1:1000, including DMSO 0.1% as vehicle control.
After 48 h, cells were harvested by scraping and washed
twice with cold PBS, then centrifuged at 13,300 rpm for
10min at 4 °C. 150 μl lysis buffer (1% Triton X-100, 50
mM HEPES, pH 7.4, 150mM NaCl, 1.5 mM MgCl2, 1
mM EGTA, 100mM NaF, 10 mM Na pyrophosphate, 1
mM Na3VO4, 10% glycerol, containing protease and
phosphatase inhibitors (Roche Applied Science)) was
then added and incubated on ice for 20 min. Samples
were centrifuged at 13,300 rpm for 10 min at 4 °C and
the supernatant collected. The protein concentration
was determined using Coomassie Plus Protein Assay
(ThermoFisher Scientific). Samples were adjusted to a
final protein concentration of 2 mg/ml. Lysates were
then mixed with 4x SDS sample buffer, heated to 80 °C
for 3 min then stored at − 80 °C ready for RPPA analysis.
Xenograft model
MM.1S tumors were established by subcutaneous injec-
tion of 1 × 107 cells into the flank of 7-week-old female
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice (n = 9 per
group). Once tumors were established, mice were treated
with vehicle (1% beta-cyclodextrin/saline), 1 mg/kg po
trametinib daily, 1 mg/kg/d ip dexamethasone every 5/7
d or their combination for up to 20 d [18, 19]. Tumor
volume was calculated from caliper measurements (4/3π
x (1 dia/4 + 2dia/4)3) and body weights were determined
three times weekly. All animal studies were approved by
the local research ethics committee and carried out in
accordance with the UK animals (Scientific Procedures)
Act 1986 and National Guidelines [20]. No blinding of
groups was done.
Results
RAS-mutant myeloma cell lines demonstrate differential
sensitivity to RAS-MAPK pathway inhibition
We first utilized the Cancer Dependency Map (www.
depmap.org) to confirm RAS dependency in the available
panel of 18 cell lines. The data analysed was based on
CRISPR-Cas9 essentiality screens performed at the
Broad Institute, with dependency measured using the
CERES score [21]. Low CERES scores were frequently
associated with NRAS and KRAS mutations, indicating
these cell lines are highly dependent on NRAS and KRAS
respectively (Fig. 1a). We chose to focus our studies on
these cell lines and included the steroid-resistant
MM.1R cell line as a potential negative control for the
effects of dexamethasone.
We examined the effect of trametinib (Tra) and dexa-
methasone (Dex) on cell proliferation in our cell line
panel. All lines were treated with an 8-point dose titra-
tion of Tra (0–1000 nM) and Dex (0–1000 nM) for 5
days (d) and cell viability assessed using CellTiter-Blue
assay (Fig. 1b). The KRAS-mutant cell lines MM.1S and
RPMI-8226 displayed sensitivity to trametinib with GI50s
of 35 nM ± 8.7 and 16.7 nM ± 3.3 respectively, while the
NRAS-mutant cell lines JJN3 and L363 were more resist-
ant (GI50 > 100 nM) (Fig. 1b). Interestingly, MM.1R was
more resistant to trametinib, compared to the MM.1S
cell line (GI50 > 100 nM). The KRAS/NRAS
wildtype cell
line LP1 was insensitive to trametinib. MM.1S,
RPMI-8226, JJN3 and LP1 were relatively sensitive to
dexamethasone, with GI50s ranging from 20 to 180
nM, while MM.1R and L363, were resistant (GI50 >
1000 nM), consistent with previous published data
[14, 22–25] (Fig. 1b).
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The fact that the MM.1S and MM.1R lines responded
differently to MEK inhibition was an interesting finding
as these are both derived from the MM.1 line, with the
key difference being the latter lacking a GR, raising the
potential for convergence between GR-mediated and
RAS-MAPK signalling [26]. Therefore, we confirmed
target engagement of both trametinib and dexametha-
sone using known pharmacodynamic biomarkers
phospho-ERK1/2 [18] and FKBP5 [27] in MM.1S and
MM.1R cells (Fig. 1c). Interestingly, irrespective of their
Fig. 1 RAS-mutant MM cell lines show variable sensitivity to trametinib. a. RAS mutation status and dependency in multiple myeloma cell lines
(www.depmap.org). b. A panel of multiple myeloma cell lines was exposed to a titration of trametinib or dexamethasone for 5 d. Cell
proliferation was assessed by CellTiter-Blue assay. Data are representative of 3 independent experiments carried out in triplicate. c. MM.1S and
MM.1R cells were treated with a titration of trametinib for 24 h and cell lysates analysed by Western blotting for the indicated proteins. Data are
representative of 3 independent experiments. Blot images were cropped for clarity of presentation. d. MM.1S and MM.1R cells were treated with a
titration of dexamethasone for 24 h and cell lysates analysed by Western blotting for the indicated proteins. Data are representative of 3
independent experiments. Blot images were cropped for clarity of presentation
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sensitivity to MEK inhibition, suppression of phospho-
ERK1/2 was observed at 30–100 nM in both the MM.1S
and MM.1R lines. As anticipated, induction of FKBP5
following dexamethasone treatment of 10 nM or greater
was observed in the MM.1S cells, while no change was
seen in MM.1R cells. We were therefore confident that
concentrations of 30 nM trametinib and 100 nM dexa-
methasone were eliciting the expected molecular
changes in these cell lines and would be used for further
mechanistic studies.
Trametinib combined with dexamethasone demonstrates
synergistic cytotoxic activity in the steroid-sensitive KRAS-
mutant line MM.1S
Dexamethasone plays an important role in myeloma
clinical practice as this is known to augment anti-MM
activity, particularly when combined with the IMiDs and
PIs [28, 29]. Therefore, we examined the influence of
dexamethasone combined with trametinib in our cell
line panel. Cells were treated with a matrix of trametinib
(range 0–300 nM) and dexamethasone (0–100 nM) for 5
d and cell proliferation was measured using CellTiter-
Blue assay. Synergy was assessed using the Bliss Inde-
pendence model, where values greater than 0 indicated
synergy [30] (Fig. 2a). The Tra/Dex combination demon-
strated synergy, particularly in the steroid-sensitive cell
lines MM.1S, RPMI-8226 and JJN3, with maximum bliss
scores of 0.3 observed (Fig. 2a). No synergy was observed
in the KRAS-mutant MM.1R, the NRAS-mutant L363 or
the KRAS/NRAS-wildtype LP1 cell lines (Fig. 2a). While
both MM.1S and JJN3 cells were TP53-wildtype and
sensitive to the Tra/Dex combination, so was the TP53-
mutant cell line RPMI8226, suggesting that TP53 muta-
tion status was unlikely to influence the response to
Tra/Dex, although more cell lines would need to be
tested for a conclusive assessment.
To investigate the mechanism of synergistic, antiprolif-
erative activity of trametinib and dexamethasone,
MM.1S, MM.1R, RPMI8226, JJN3 and L363 cell lines
were incubated with DMSO 0.1%, trametinib 30 nM,
dexamethasone 100 nM and their combination for 5 d
and apoptosis quantified using annexin V/PI staining
and flow cytometry (Figs. 2b and S1A). There was a sig-
nificant increase in the proportion of apoptotic cells
treated with the trametinib/dexamethasone combination
particularly in the MM.1S line, with 85.2 ± 6.9% com-
bined Annexin V+ and Annexin V+/PI+ cells observed.
In RPMI8226 cells, the combination appeared to be
additive and in JJN3 cells, the combination led to signifi-
cantly greater apoptosis versus single agents. Little
change was observed in the MM.1R cells. Cell cycle ana-
lysis demonstrated an increased proportion of sub-G1
cells observed with combination treatment in the
MM.1S cells, consistent with cell death (Fig. S1B).
As our overall aim was to identify a novel drug com-
bination for RAS-mutant myeloma that would translate
clinically to durable remission and improved patient sur-
vival, we sought to investigate the effect of prolonged, 3-
week treatment with trametinib and dexamethasone. We
selected the MM.1S cell line, as this had demonstrated
the greatest sensitivity to these drugs from our viability
and apoptosis assays. Cells were seeded at a density to
allow for logarithmic growth and treated with selected
concentrations of DMSO 0.1%, trametinib (30 nM),
dexamethasone (100 nM), or their combination. Cell
numbers were measured every 2–3 d using Trypan Blue
staining. To assess the effect of these drugs on cell pro-
liferation, we calculated the number of population dou-
blings over time (Fig. 2c). Prolonged treatment with
trametinib slowed the proliferation of MM.1S cells in
comparison to our vehicle control DMSO 0.1% but
failed to arrest proliferation completely. In contrast,
dexamethasone treatment did not significantly inhibit
cell proliferation. However, the combination of these
drugs resulted in an initial loss of cells, followed by a
sustained antiproliferative effect throughout the
remaining treatment period.
We next confirmed the effect of trametinib and dexa-
methasone on downstream signalling over a 72 h time
course. MM.1S cells were treated with DMSO 0.1%, tra-
metinib 30 nM, dexamethasone 100 nM or their combin-
ation for 24, 48 and 72 h (Fig. 2d). We observed
induction of FKBP5 and suppression of phospho-ERK1/
2 levels with both dexamethasone and trametinib re-
spectively over the 72 h time course. Consistent with cell
death induced by the combination, we observed cleavage
of poly-ADP ribose polymerase (PARP), indicative of
apoptosis. This was associated with the induction of
BIM expression, and, strikingly, MCL-1 expression was
decreased with this treatment combination, which was a
significant finding as this is known to play a critical role
in driving MM cell survival and has been associated with
adverse prognosis in myeloma patients [31, 32].
Proteomic identification of candidate signalling effectors
Reverse Phase Proteomic Array (RPPA) is a rapid, high-
throughput method that allows large-scale analysis of
phosphorylation changes from in vitro and clinical sam-
ples [33]. We used RPPAs to examine the phosphopro-
teome to identify key sensitising pathways in KRAS-
mutant myeloma cell lines treated with trametinib and
dexamethasone. A custom RPPA panel was used to
identify candidate pathways modulated by trametinib/
dexamethasone treatment in the KRAS-mutant MM.1S
and MM.1R lines (Table S1). These were treated with
DMSO 0.1% as vehicle control, trametinib 30 nM, dexa-
methasone 100 nM and their combination for 48 h. All
treated samples were analyzed in triplicate, with the
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Fig. 2 (See legend on next page.)
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mean values normalized to vehicle control and grouped
using hierarchical clustering (Morpheus software) (Fig. 3a).
Initial analysis identified five phosphoproteins of interest
that demonstrated significant change at 48 h following
trametinib/dexamethasone combination in MM.1S cells:
FAK (Tyr397), FLT3 (Tyr591), NDRG1 (Thr346), PYK2
(Tyr402) and 4EBP1 (Thr37/Thr46) (Fig. 3a). To identify
phosphoproteins that may impact upon the activity ob-
served in the MM.1S cells but was not seen in the MM.1R
cells, we compared their expression levels in MM.1S versus
MM.1R following treatment with trametinib and dexa-
methasone combination (Fig. 3b). Overall, a greater reduc-
tion in the nominated phosphoproteins was observed in the
MM.1S line compared to MM.1R, with FLT3 (Tyr591),
FAK (Tyr397), NDRG1 (Thr346), 4EBP1 (Thr37/Thr46),
STAT1 (Tyr701) and PYK2 (Tyr402) showing the greatest
suppression. Overall, a greater reduction in expression level
was observed with combination treatment for all nomi-
nated phosphoproteins, compared to either trametinib or
dexamethasone alone (Fig. 3c). The most significant
changes were seen in NDRG1, with the relative expression
falling to 0.51 ± 0.02 with combination treatment compared
to 0.83 ± 0.02 and 0.90 ± 0.02 with trametinib and dexa-
methasone alone respectively.
NDRG1 is regulated by the serum- and glucocorticoid-
inducible kinase-1 (SGK1), through phosphorylation at
sites Thr328, Ser330 and Thr346 [34–36]. SGK1 itself is a
serine/threonine kinase that shares a similar structure and
function to Protein Kinase B (AKT) and Ribosomal S6
Kinase (S6K), and is completely activated by mammalian
target of rapamycin complex 2 (mTORC2) and 3-
phosphoinositol-dependent kinase 1 (PDK1) [37–39]. The
latter in particular has generated increasing interest
as, following phosphorylation at the Ser241 site by
PI3K, PDK1 activates multiple downstream effectors,
including SGK1, AKT (through phosphorylation at
the Thr308 residue), and p70 ribosomal S6 kinase
(p70S6K) [40, 41]. These have all been implicated in
driving tumorigenesis through uncontrolled cell prolif-
eration, invasiveness and metastasis, making PDK1 a
potential therapeutic target [42].
Combined trametinib/dexamethasone treatment
suppresses PDK1-NDRG1 signaling
We confirmed our RPPA findings by immunoblotting, in
both MM.1S and MM.1R cells. These cell lines were
treated with DMSO 0.1% as vehicle control, trametinib
30 nM, dexamethasone 100 nM and their combination
for up to 72 h (Fig. 3d). We observed downregulation of
the candidate phosphoproteins FLT3 (Tyr591), NDRG1
(Thr346), PYK2 (Tyr402) and 4EBP1 (Thr37/Thr46)
with combination treatment in the MM.1S line, in keep-
ing with our RPPA data, with maximal changes observed
at 72 h. Interestingly, when examining the same candi-
dates in the resistant MM.1R line, while phospho-FAK
and phospho-PYK2 were suppressed by trametinib/dexa-
methasone combination, both phospho-NDRG1 and
phospho-4EBP1 levels were relatively unchanged,
highlighting these as potentially important biomarkers of
this drug combination in the sensitive MM.1S cell line
(Fig. 3d).
PDK1 (PDPK1) is a potential therapeutic target in multiple
myeloma
Interestingly, combined RNAi screens (Broad Institute,
Novartis and Marcotte), demonstrate that multiple mye-
loma shows a high dependency on the PDPK1 gene,
which encodes PDK1 (Fig. S2) [43]. Moreover, the ex-
pression of NDRG1 was significantly elevated in both
the NRAS-mutant JJN3 line and the KRAS-mutant
MM.1S line, both of which had demonstrated the stron-
gest synergistic anti-proliferative response following tra-
metinib and dexamethasone treatment (Fig. 4a and b).
Overall, these data highlighted PDK1 as a potentially im-
portant pro-survival pathway in multiple myeloma.
To explore this further, the MM.1S and MM.1R cells
were treated with the PDK1 inhibitor (PDK1i)
GSK2334470. This compound is one of the first PDK1
inhibitors to demonstrate specific and potent activity
in vitro, with an IC50 of 10 nM, and associated sup-
pression of phospho-AKT (Thr308), phospho-NDRG1
(Thr346) and SGK1 [44]. In multiple myeloma, this
compound had demonstrated antiproliferative activity
(See figure on previous page.)
Fig. 2 The combination of trametinib and dexamethasone is synergistic and glucocorticoid receptor-dependent. a. A panel of multiple myeloma
cell lines was exposed to a matrix of trametinib and dexamethasone for 5 d. Cell proliferation was assessed by CellTiter-Blue assay and synergy
calculated using the Bliss independence model. Data are representative of 3 independent experiments carried out in triplicate. b. MM.1S,
MM.1R, RPMI8226, JJN3 and L363 cell lines were exposed to DMSO, 30 nM trametinib, 100 dexamethasone or the combination of
trametinib and dexamethasone for 5 d. Cells were fixed, stained for annexin V and analysed by flow-cytometry. The number of early and
late apoptotic cells combined is expressed as a percentage of total cells. Data are representative of 3 independent experiments. c. MM.1S
cells were treated with trametinib, dexamethasone or their combination and cumulative cell doublings determined by cell counting.
Significance was determined by two-way Anova *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. Data are representative of 3 independent
experiments. d. MM.1S cells were treated with DMSO, 30 nM trametinib, 100 nM dexamethasone or their combination for the indicated
times and cell lysates analysed by Western blotting for the indicated proteins. Data are representative of 3 independent experiments. Blot
images were cropped for clarity of presentation
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in a panel of cell lines, with associated suppression of
the PI3K-mTOR pathway, and enhanced apoptosis
[45]. Cell lines were treated with an 8-point dose titra-
tion of this compound for 5 d and cell viability was
measured using the CellTiter-Blue assay. Interestingly,
irrespective of their differential response to trametinib
and dexamethasone, both the MM.1S and MM.1R cells
were sensitive to GSK2334470, with GI50s of 3.7 ±
2 μM and 6.7 ± 1 μM respectively (Fig. 4c). The activity
of this compound was confirmed through immuno-
blotting, with suppression of phospho-PDK1, phospho-
NDRG1 and phospho-S6 observed following a 48 h
treatment in the MM.1S cells (Fig. 4d).
IGF-1 confers resistance to the combination of trametinib
and dexamethasone
Insulin growth factor-1 (IGF-1) is well known to play a
critical role in driving myeloma cell survival through ac-
tivation of distinct downstream signalling pathways inde-
pendent of the cytokine IL-6 [46]. More specifically,
IGF-1 has recently been shown to mediate cancer cell
survival through direct modulation of the PDK1 path-
way, with enhanced phosphorylation of PDK1 observed
following IGF-1 stimulation [47]. Importantly, as well as
driving MM cell survival, IGF-1 has also been shown to
mediate drug resistance, including to dexamethasone,
which could be reversed when cells were treated with ei-
ther the PI3K inhibitor LY294002 or the mTOR inhibi-
tor rapamycin, but not with the MAPK inhibitor
PD98059 [48]. We therefore examined the influence of
IGF-1 on sensitivity to the trametinib/dexamethasone
combination. Firstly, MM.1S cells were stimulated with
IGF-1 to confirm its effect on PDK1 signalling, with acti-
vation of the IGF-1 receptor (IGF-1R), induction of
phospho-PDK1, phospho-AKT and phospho-NDRG1
observed (Fig. 4e). Subsequently, we treated this cell line
with GSK2334470 alone, trametinib, dexamethasone and
their combination, at concentrations known to modulate
biomarker changes, for 72 h in the presence or absence
of IGF-1 (Fig. 4f). IGF-1 protected cells from the anti-
proliferative effects of both GSK2334470 and dexa-
methasone, while the response to trametinib was not
significantly affected. Notably, the presence of IGF-1
conferred resistance to combined treatment with
trametinib/dexamethasone in the MM.1S line, with cell
proliferation significantly increasing to 31.0% ± 0.04 of
control with IGF-1 compared to 4.4% ± 0.01 without
IGF-1. In contrast, addition of IL-6 to cells treated with
the combination of trametinib and dexamethasone had
no significant effect on cell proliferation (Fig. 4g).
The RAF-MEK inhibitor RO5126766 also shows synergy
with dexamethasone
The RAF-MEK inhibitor RO5126766 (CH5126766) is
currently being tested in RAS-mutant patients in the
Phase I setting (NCT02407509). While there is an option
to add in steroids, two myeloma patients had received
RO5126766 alone, of which one of them (carrying both
NRAS and KRAS mutations) achieved a partial response
[49]. We were interested in examining the potential
combination of RO5126766 with dexamethasone, to ob-
serve if this also demonstrated synergistic activity.
MM.1S cells were treated with a matrix of RO5126766
(range 0–1000 nM) and dexamethasone (0–100 nM) for
5 d, and cell proliferation determined by CellTiter-Blue
assay and synergy assessed using the Bliss Independence
model (Fig. S3A). Reassuringly, synergistic activity was
also observed between RO5126766 and dexamethasone
in the MM.1S line, with a bliss score of 0.3.
We explored the effect of these drugs on downstream
signalling pathways, and observed suppression of
phospho-ERK1/2 by RO5126766, while FKBP5 was in-
duced in the presence of dexamethasone (Fig. S3B). Im-
portantly, as seen with trametinib, the combination of
these drugs suppressed biomarkers correlating to the
PDK1 pathway, particularly phospho-NDRG1 (Thr346)
and phospho-4EBP1 (Thr37/Thr46). Additionally, sup-
pression of MCL-1 and induction of BIM, was also ob-
served (Fig. S3B). Taken together, these results raise
confidence that synergy is a result of MEK inhibition
and not due to an as yet undiscovered off-target effect of
trametinib.
The combination of trametinib and dexamethasone has
modest efficacy in vivo
The antitumor activity of combined trametinib/dexa-
methasone was investigated in vivo in the MM.1S xeno-
graft. Trametinib was administered daily, continuously
(See figure on previous page.)
Fig. 3 Suppression of PDK1-NDRG1 signaling is associated with the response to combined trametinib and dexamethasone. a. MM.1S and MM.1R
cells were treated with trametinib, dexamethasone or their combination for 48 h. Cell lysates were analysed in triplicate by RPPA for the indicated
proteins. Hierarchical clustering of the log2 fold-change in expression relative to the DMSO control is presented. b. Scatter plot of the log2 fold-
change in protein expression from the RPPA analysis comparing the MM.1S and MM.1R cells treated with the combination of trametinib and
dexamethasone for 48 h. c. Decreased expression of candidate proteins for the combination of trametinib and dexamethasone relative to single
agent treatment in MM.1S cells. Significance was determined by two-way Anova *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (n = 3). d. MM.1S
and MM.1R cells were treated with DMSO, trametinib (30 nM), dexamethasone (100 nM) or their combination for 24, 48 and 72 h. Cell lysates were
analysed by Western blotting for the indicated proteins. Data are representative of 3 independent experiments. Blot images were cropped for
clarity of presentation
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Fig. 4 Basal PDK1-NDRG1 signaling is associated with the response to combined trametinib and dexamethasone. a. A panel of multiple myeloma
cell lines was analysed by Western blotting for expression and phosphorylation of NDRG1. Vinculin was used as a loading control. Data are
representative of 4 independent experiments. Blot images were cropped for clarity of presentation. b. Quantification of total NDRG1 expression
normalised to the vinculin loading control. Significance was determined by one-way Anova *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (n =
4). The magnitude of synergy observed with the combination of trametinib and dexamethasone is indicated (‘-‘ none, ‘+’ low, ‘++’ high). c. MM.1S
and MM.1R cells were exposed to a titration of the PDK1 inhibitor GSK2334470 for 5 d. Cell proliferation was assessed by CellTiter-Blue assay. Data
are representative of 3 independent experiments. d. MM.1S cells were treated with 3 μM GSK2334470 for 48 h and cell lysates analysed for the
indicated proteins by Western blotting. Data are representative of 3 independent experiments. Blot images were cropped for clarity of presentation. e.
MM.1S cells were treated with either 0.5% BSA (control) or 100 ng/ml of IGF-1 for 10min. Cell lysates were analysed by Western blotting for the
indicated proteins. Blot images were cropped for clarity of presentation. f. MM.1S cells were treated with either 0.5% BSA or 100 ng/ml IGF-1 and then
exposed to either 3 μM GSK2334470, 30 nM trametinib, 100 nM dexamethasone or the combination of trametinib and dexamethasone for 5 d. Cell
proliferation was determined by CellTiter-Blue assay. Significance was determined by two-way Anova *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001
(n = 3). g. MM.1S cells were treated with either 0.5% BSA or 3 ng/ml IL-6 and then exposed to either 30 nM trametinib, 100 nM dexamethasone or the
combination of trametinib and dexamethasone for 5 d. Cell proliferation was determined by CellTiter-Blue assay. Significance was determined by two-
way Anova *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (n = 3)
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and dexamethasone was administered on a 5 d on, 2 d
off schedule according to prior reports and tumor
growth measured [18, 19]. Trametinib treatment caused
a modest, but not significant, increase in tumor growth,
whereas dexamethasone treatment delayed tumor
growth, though this too was not significant. However,
modest but significant tumor growth inhibition was ob-
served between the vehicle control group and the com-
bined trametinib/dexamethasone group in the MM.1S
tumors (Fig. 5b). No significant body weight loss was ob-
served with the combined treatment versus control
MM.1S tumors, suggesting this combination is tolerable
(Fig. 5c).
Discussion
The RAS oncogene has gained significant interest in
multiple myeloma as this has been associated with ad-
vanced, refractory disease, resulting in the development
of targeted therapies against the RAS-MAPK signalling
cascade in RAS-mutant MM patients [6]. However, to
date, trametinib, either as a single agent or in combin-
ation with IMiDs or AKT inhibitors has had limited suc-
cess in the clinical setting, due to rapidly progressive
disease and unmanageable toxicities [8, 50]. Corticoste-
roids are commonly used in clinical practice in oncology
to manage the side effects associated with BRAF and
MEK inhibitors, including trametinib [51]. Additionally,
dexamethasone also enhances clinical activity of all ap-
proved anti-myeloma therapies, despite an insufficiently
understood molecular mechanism. Therefore, we were
interested in exploring the efficacy of trametinib with
dexamethasone for the treatment of RAS-mutant mul-
tiple myeloma.
Our study shows that trametinib combined with dexa-
methasone demonstrates synergistic cytotoxic activity in
MMCLs, associated with decreased MCL1 expression
and the induction of BIM. Interestingly, the steroid-
resistant line MM.1R is resistant to both trametinib and
dexamethasone single treatment, indicating a potential
crosstalk between the glucocorticoid receptor and RAS-
MAPK signalling pathways. Through RPPA, we identify
the PDK1 pathway to be a potential biomarker of sensi-
tivity to this combination, with suppression of NDRG1
and 4EBP1 observed in the sensitive MM.1S cells follow-
ing combined trametinib/dexamethasone treatment,
while these remain unaltered in the resistant MM.1R
cells. Interestingly, RNAi screens have shown the mye-
loma lineage is highly dependent on PDK1 (encoded by
PDPK1) and elevated basal NDRG1 levels observed in
the JJN3 and MM.1S cell lines, are associated with sensi-
tivity to combined treatment with trametinib and dexa-
methasone. Therefore, NDRG1 expression deserves
further evaluation as a biomarker to stratify patients for
this therapeutic strategy.
We show that addition of recombinant IGF-1 but not
IL-6 is able to blunt the antiproliferative effect of com-
bined trametinib and dexamethasone treatment, poten-
tially through reactivation of the PDK1 pathway. Notably,
IGF-1R is amplified and is the top-ranking dependency in
multiple myeloma as assessed by RNAi screens. Moreover,
myeloma cell lines show a differential sensitivity to mul-
tiple IGF-1R inhibitors (www.depmap.org). There has
been much excitement over the use of IGF-1R inhibitors
for the treatment of multiple myeloma but these have not
progressed clinically. Our data suggest further investiga-
tion of IGF-1R inhibitors in combination with MEK inhib-
ition and dexamethasone, possibly in those patients whose
tumor cells show amplification of IGF-1R or elevated ex-
pression of NDRG1, may be warranted.
The bone marrow microenvironment plays an import-
ant role in driving myeloma cell survival, through their
interaction with the stromal cells and associated release
of growth factors and cytokines [52]. Therefore, given
our demonstration that IGF-1 confers resistance to
Fig. 5 The combination of trametinib and dexamethasone
suppresses tumor growth in vivo. a. Human MM1.S cells (107/mouse)
were inoculated subcutaneously into the flank of NSG mice, n = 9
mice per group. Once tumors were established, mice were treated
with either vehicle, 1 mg/kg/d po trametinib continuously, 1 mg/kg
dexamethasone ip (5 d on, 2 d off schedule), or the combination of
trametinib and dexamethasone for up to 20 d. Tumor volume was
measured by callipers every 3–5 d, and the mean volume per group
was expressed as a percentage relative to day 0; error bars represent
standard error. Statistical significance was determined using one-way
Anova of relative tumor volumes after 13 d of dosing. b. The body
weight of the mice from each group in B was measured and the
mean per group was expressed as a percentage change from day 0;
error bars represent standard error
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combined trametinib and dexamethasone, it was possible
that the synergistic effects observed in myeloma cells
cultured in vitro may be blunted in vivo due to signalling
cues from the supporting stroma. Notably, trametinib
treatment resulted in modestly (but statistically insignifi-
cant) accelerated tumor growth. We speculate that this
could be due to loss of negative feedback mechanisms
that results in activation of RTKs, which may sustain or
enhance tumor growth. Nevertheless, only the combin-
ation of both drugs significantly reduced tumor growth
versus vehicle. However, the in vivo anti-tumor activity
of this combination was limited and we hypothesise that
growth factors within the tumor microenvironment may
contribute to this reduced response. It should also be
noted that the dosing regimen used was based on pub-
lished data and may not have been optimal for the
model used. Furthermore, it was not possible to assess
biomarker changes within the tumors post-dosing which
would have confirmed target engagement and the extent
of pathway modulation.
To validate MEK as the key target underlying the syn-
ergistic activity of combined trametinib and dexametha-
sone, we used a chemically-distinct MEK inhibitor
RO5126766 and confirmed that this compound also
demonstrates synergistic activity with dexamethasone
and induces the same molecular effects as seen with
trametinib. As discussed earlier, RAS-mutant myeloma
patients are currently being enrolled in a phase I study
of RO5126766 (NCT02407509) with some clinical re-
sponses observed. Our data therefore supports the clin-
ical investigation of dexamethasone in combination with
a MEK inhibitor for RAS-mutant myeloma patients.
Interestingly, the data herein does suggest a potential
interaction between the RAS-MAPK and GR-mediated
signalling pathways. One possible interpretation is that
GR activation by dexamethasone enhances cellular de-
pendency on the MAPK pathway. Given that loss of the
GR appears to confer resistance to trametinib, it would
appear that GR loss may reduce dependency on MAPK
signalling. A more comprehensive analysis of the differ-
ential dependencies between these two cell lines may
shed further light on this observation.
Future work to investigate this further would be directed
at mechanistically validating the role of PDK1 through
siRNA or even CRISPR-Cas9-mediated knockdown of key
targets, including PDPK1 and NDRG1. The latter in par-
ticular would be of interest as this was highlighted as a po-
tential biomarker, being highly expressed in those cell
lines that demonstrated the greatest susceptibility to the
trametinib and dexamethasone combination.
Conclusion
In conclusion, we have identified that the combination
of trametinib and dexamethasone is synergistic in RAS-
mutant myeloma cells, particularly in those with elevated
NDRG1 expression and is associated with suppression of
PDK1 signalling. Our data supports further exploration
of this combination, but also helps to further our under-
standing of how the glucocorticoid receptor may drive
MM cell death, which could direct future therapeutic
strategies for this cancer type.
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